Genetic modification of the diarrhoeal pathogen *Cryptosporidium parvum*

Sumiti Vinayak^{1*}, Mattie C. Pawlowicz^{1*}, Adam Sateriale^{1*}, Carrie F. Brooks¹, Caleb J. Studstill¹, Yael Bar-Peled¹, Michael J. Cipriano¹ & Boris Striepen^{1,2}

Recent studies into the global causes of severe diarrhoea in young children have identified the protozoan parasite *Cryptosporidium* as the second most important diarrhoeal pathogen after rotavirus^{1–3}. Diarrhoeal disease is estimated to be responsible for 10.5% of overall child mortality⁴. *Cryptosporidium* is also an opportunistic pathogen in the contexts of human immunodeficiency virus (HIV)-caused AIDS and organ transplantation^{5,6}. There is no vaccine and only a single approved drug that provides no benefit for those in gravest danger: malnourished children and immunocompromised patients^{7,8}. *Cryptosporidiosis* drug and vaccine development is limited by the poor tractability of the parasite, which includes a lack of systems for continuous culture, facile animal models, and molecular genetic tools^{3,9}. Here we describe an experimental framework to genetically modify this important human pathogen. We established and optimized transfection of *C. parvum* sporozoites in tissue culture. To isolate stable transgenics we developed a mouse model that delivers sporozoites directly into the intestine, a *Cryptosporidium* clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 system, and *in vivo* selection for aminoglycoside resistance. We derived reporter parasites suitable for *in vitro* and *in vivo* drug screening, and we evaluated the basis of drug susceptibility by gene knockout. We anticipate that the ability to genetically engineer this parasite will be transformative for

Cryptosporidium research. Genetic reporters will provide quantitative correlates for disease, cure and protection, and the role of parasite genes in these processes is now open to rigorous investigation.

Cryptosporidium infection occurs through faecal oral transmission of the environmentally resilient oocyst. The oocyst shelters four sporozoites that emerge in the small intestine and invade the epithelium. Although there is no tissue culture system for continuous passage, *C. parvum* development can be observed for 2–3 days by infecting human ileocaecal adenocarcinoma cells (HCT-8)¹⁰. To achieve transfection, sporozoites were excysted from oocysts purified from the faeces of experimentally infected calves using a protocol that mimics stomach and intestinal passage¹¹, and then electroporated before infection of HCT-8 cells (Fig. 1a). The transfection plasmids used here flanked a variety of reporter genes with candidate *C. parvum* 5' and 3' regulatory sequences derived from highly expressed housekeeping genes. We observed significant reporter activity 48 h after transfection using plasmids carrying nanoluciferase (Nluc; Fig. 1b), a small ATP-independent enzyme from deep sea shrimp¹², but not firefly luciferase or fluorescent proteins. Nluc luminescence correlated with the number of parasites and the amount of DNA used for transfection. Luminescence was also shown to require the presence of parasite-specific promoter elements and the introduction of DNA into parasites and not host cells (Fig. 1).

Figure 1 | Transfection of *C. parvum*. **a**, Schematic overview. *C. parvum* sporozoites were prepared from oocysts purified from infected calves and electroporated in the presence of plasmid DNA before infection of HCT-8 cells (Eno, flanking sequence from the *C. parvum* enolase gene). **b–j**, Luminescence measurements (the means of three technical replicates, standard deviation (s.d.) shown as error bars) of *C. parvum* (**b–e**, **h–j**, blue), *T. gondii* (**f**), or human HCT-8 cells (**g**) transfected with Nluc expression plasmids. **b–d**, *C. parvum* transfection requires electroporation (**b**) of DNA (**c**) into parasites (**d**). **e**, **f**, **h**, Transfection also requires plasmids to carry parasite-specific promoter sequences (**e**, **f**; testing *C. parvum* (Cp) and *T. gondii* (Tg) promoters in both

parasites), and is susceptible to the *Cryptosporidium* drug nitazoxanide (**h**). **g**, Lipofection of HCT-8 cells with the original Nluc plasmid pNL1.1 (Promega), but not derived parasite vectors, results in luciferase activity in the host alone. Choice of promoter (**i**; enolase (Eno), aldolase (Aldo), α -tubulin 5' regions (Tub) (the 3' untranslated region (UTR) was uniformly from the enolase gene)) or codon composition (**j**; Nluc optimized to 35% GC (oNluc)) influences expression level in *C. parvum*. Note automatic gain adjustment of luminescence measurements; units are not comparable between panels. Independent biological experiments were repeated three times, and representative data are shown.

¹Center for Tropical and Emerging Global Diseases, University of Georgia, Paul D. Coverdell Center, 500 D.W. Brooks Drive, Athens, Georgia 30602, USA. ²Department of Cellular Biology, University of Georgia, Paul D. Coverdell Center, 500 D.W. Brooks Drive, Athens, Georgia 30602, USA.

*These authors contributed equally to this work.

Figure 2 | Luciferase assays for *C. parvum* drug resistance and CRISPR/Cas9 activity. **a**, HCT-8 cells were infected with Nluc-transfected sporozoites and grown for 2 days in the presence of paromomycin. **b**, Translational fusions were constructed placing Neo at the amino or carboxy terminus of Nluc. Nluc-Neo shows luciferase activity, albeit at a reduced level when compared to Nluc alone. **c**, *C. parvum* transfected with Nluc (blue) or Nluc-Neo (red) were grown in different concentrations of paromomycin. Luciferase activity for each plasmid was normalized to its drug-free level. **d**, CRISPR/Cas9 plasmid for *C. parvum*. Flag, epitope tag; nls, nuclear localization signal; ribo, ribosomal protein L13A 3' UTR; u6, newly annotated promoter CM000433:553110–553472. **e**, **g**, Outline (**e**) and sequences (**g**) for Nluc repair assay. Guide RNA target, blue; protospacer adjacent motif, green; mutagenized codon 18, red. **f**, Sporozoites were transfected with Nluc or a codon 18 termination mutant (Dead Nluc); note ablation of signal. In addition to the Dead Nluc plasmid, some parasites also received a 125 bp double-stranded repair DNA fragment, and the Cas9 plasmid with the indicated guide RNAs (gRNAs; no target, empty gRNA cassette; off target, GFP gRNA; on target, Nluc gRNA). Statistical analysis compares Dead Nluc alone with Dead Nluc and Cas9 and specific gRNA. Note significant Cas9-mediated restoration of luciferase activity ($***P = 0.0006$, unpaired *t*-test). $n = 3$ technical replicates for **a–c**, and controls from **f**; $n = 6$ technical replicates for on-target samples in **f**. Error bars are s.d. and all experiments depicted here were repeated three times and representative data are shown.

Furthermore, reporter signal was ablated by the anti-parasitic drug nitazoxanide. Transient transfection of *C. parvum* is inefficient ($<10,000$ fold when compared to the related apicomplexan *Toxoplasma gondii* in parallel experiments) and requires a highly sensitive reporter such as Nluc to be noticeable.

In an effort to enhance efficiency we evaluated different electroporation devices, electrical wave programs and buffer compositions (Extended Data Fig. 1); this produced tenfold enhancement. We tested flanking sequences from different *C. parvum* genes and identified the enolase promoter to be strongest. The *C. parvum* genome is AT rich and shows strong codon bias¹³. We also noted a preference for A over T within the first 20 codons and thus explored codon optimization and found sixfold enhancement (Fig. 1j).

To enable enrichment of transgenic parasites, we next explored the selection of drug resistance. The aminoglycoside antibiotic paromomycin does not cure cryptosporidiosis in people, but is effective in tissue culture (Fig. 2a) and in immunocompromised mice¹⁴. Work in other protist models has shown aminoglycoside phosphotransferases to

Figure 3 | Mouse model for selection of stable *C. parvum* transgenics.

a, Outline of the selection strategy. Transfected sporozoites were injected into the small intestine by surgery (Extended Data Fig. 2) and mice were treated with paromomycin. Oocysts were purified from the faeces and used to infect cultures or mice by oral gavage. **b**, Quantitative PCR of *C. parvum* DNA isolated from faeces of mice infected with transfected sporozoites (four mice per group) and treated as indicated. Emergence of paromomycin resistance required the Nluc-Neo and Cas9 plasmids. **c**, **d**, Upon reinfection, parasites show strong drug resistance (**c**) and luciferase activity (**d**). In repeat experiments we noted that luciferase is detectable as early as 6 days after transfection in the faeces of the first infected mouse (Extended Data Fig. 4). **e**, Protein extracts from oocysts were analysed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and western blot using an antibody against Neo (rabbit anti-neomycin phosphotransferase II; EMD Millipore). Predicted molecular mass of the Nluc-Neo fusion protein is 48.3 kDa. **f**, Immunofluorescence staining using anti-Neo (mouse anti-Neo; Alpha Diagnostic International) and *C. parvum* (tryptophan synthase B) antibodies. Note multiple nuclei in 4',6-diamidino-2-phenylindole (DAPI) stain typical for *C. parvum* meronts. No anti-Neo staining was observed in wild-type parasites. **g**, Luciferase assays for HCT-8 cultures infected with wild-type (WT; blue) and transgenic (Nluc-Neo; red) parasites. The y-axis is split to show level of luminescence background. $n = 3$ technical replicates, error bars are s.d., the experiment was done twice. **h**, Ninety-six-well luciferase drug assay using 1,000 oocysts per well. Note significant growth inhibition on treatment with 10 μ M nitazoxanide ($**P = 0.0036$, unpaired *t*-test). $n = 3$ technical replicates, error bars are s.d., the experiment was repeated two times and representative data are shown.

confer resistance to paromomycin^{15,16}. Appreciation of *C. parvum* drug resistance in culture is complicated by the lack of continuous growth. We thus constructed translational fusions between the Nluc reporter and the neomycin resistance marker (Neo)¹⁵ to focus our observation on the small subset of transfected parasites. Luciferase activity in parasites expressing Nluc-Neo showed reduced susceptibility to paromomycin treatment compared to Nluc alone (Fig. 2c), and thus we concluded that Nluc-Neo confers drug resistance in this transient assay.

Our genome searches indicated that *Cryptosporidium* species lack non-homologous end joining DNA repair. This suggested transgene integration to be rare and to require homologous recombination^{17,18}. Such recombination can be enhanced by long flanking regions and/or double-strand breaks introduced by restriction enzymes, transcription activator-like effector nucleases (TALENs) or CRISPR/Cas9 (refs 18, 19). To build a *C. parvum* CRISPR/Cas9 system, we constructed a plasmid in which the *C. parvum* U6 RNA promoter drives a guide RNA cassette²⁰ and the *Streptococcus pyogenes* Cas9 gene²¹ is flanked by parasite regulatory sequences (Fig. 2d). To test this system, we conducted a Cas9-dependent DNA repair experiment (Fig. 2e–g). We introduced a stop codon into the Nluc reporter that ablated luciferase activity (Dead Nluc). We then targeted the dead gene with a guide RNA, and provided a short double-stranded template for repair that restores read-through translation and renders the repaired gene resistant to further Cas9 cutting. When *C. parvum* sporozoites are co-transfected with a specific guide, luciferase activity is restored ($P = 0.0006$, unpaired *t*-test). No change is observed with no or off-target guides.

Interferon- γ knockout mice are susceptible to *C. parvum* infection through oral inoculation of oocysts²². However, infection with free sporozoites is less effective²³, probably due to stomach passage. We developed a surgical protocol to inject transfected sporozoites directly into the small intestine to maximize infection (Extended Data Fig. 2). When mice were killed 24 h after infection, luciferase activity was observed in scrapings of the intestinal epithelium. We also established an effective treatment protocol using paromomycin supplementation of the drinking water (Extended Data Fig. 3).

Next, we infected mice by surgery with transfected sporozoites and treated them with paromomycin as indicated (Fig. 3 and Extended Data Fig. 4; four mice per group). Faeces were collected every 3 days and oocyst shedding was measured by quantitative polymerase chain reac-

tion (PCR) targeting the *C. parvum* 18S ribosomal RNA locus. Mice infected with parasites transfected with the Nluc-Neo plasmid that did not receive drug shed high numbers of oocysts and remained infected for the 30 days observed (Fig. 3b, blue). Those infected with parasites that received the Nluc plasmid (lacking the Neo gene; Fig. 3b, green) were rapidly cured by drug treatment. Those transfected with Nluc-Neo alone and drug treated were also cured (infection may persist slightly longer). In contrast, infection with parasites carrying the Nluc-Neo plasmid and the Cas9 plasmid (Fig. 3b, red; Cas9 target detailed later) rapidly rebounded to levels similar to untreated mice. Oocysts emerging from selection were purified from faeces and used to infect mice that were again treated with paromomycin; wild-type oocysts were used in parallel (100,000 oocysts per mouse by gavage). While paromomycin treatment cured infection with wild-type parasites, transgenic parasites showed immediate robust drug resistance (Fig. 3c). When these oocysts were probed by western blot with anti-Neo antibody, we detected a band consistent with an Nluc-Neo fusion protein.

Purified oocysts were also used to infect cell cultures, and processed for immunofluorescence after 2 days. Transgenic but not wild-type intracellular parasite stages showed fluorescence when probed with antibodies specific for either Neo or Nluc (Fig. 3f and data not shown). These cultures also displayed strong luciferase activity not observed in wild type. This activity exceeded that previously observed in transient transfection experiments by five orders of magnitude on a per-cell basis. We assessed whether these organisms could be suitable for drug-screening assays by infecting 96-well plates with 1,000 oocysts per well and measured luciferase after 48 h. Infected wells were clearly distinguishable from uninfected wells ($z' > 0.6$; $n = 20$). Similarly, wells treated with nitazoxanide showed significant growth inhibition ($P = 0.0036$, unpaired *t*-test). Luciferase also provided a convenient way to assess the infection state of animals. We sampled 10 mg of faeces from mice diagnosed in parallel by PCR and found this assay to be sensitive, specific and faster than PCR (Fig. 3d). We note that Nluc expression remains stable when parasites are propagated in mice in the absence of paromomycin (Extended Data Fig. 5).

Cryptosporidium is remarkably resistant to antifolates, a mainstay of treatment against other apicomplexans, and this resistance has been attributed to differences in the target enzyme dihydrofolate reductase-thymidylate synthase (DHFR-TS)²⁴. However, *Cryptosporidium* is

Figure 4 | Targeted deletion of *C. parvum* TK. **a**, Owing to a horizontal gene transfer, *C. parvum* has two pathways to synthesize dTMP: TK and DHFR-TS. DHF, dihydrofolic acid; THF, tetrahydrofolic acid; dUMP, uridine monophosphate. **b**, Map of the *C. parvum* TK locus, the targeting plasmid and the predicted modified locus. Primers and amplicon sizes of diagnostic PCR products are indicated (Ins, insertion). **c**, PCR analysis using genomic DNA from wild-type (WT) and transgenic parasites (Nluc-Neo, oocysts purified from faeces of infected mice shown in Fig. 3c; CDS, coding sequence). Primer sequences are provided in Supplementary Table 1. **e**, Quantification of EdU-labelling experiments (meronts with four or more nuclei were scored, two

biological repeats, $n = 105$ each sample, error bars are s.d.). **d**, Representative fluorescence micrographs are shown. Antibody to *C. parvum* tryptophan synthase B was used to identify parasites (green). **f**, Trimethoprim treatment of wild-type (blue) and Nluc-Neo transgenic (red) parasites. Wild-type parasites were measured in transient transfection assays with Nluc plasmid ($n = 3$, technical replicates, error bars are s.d.). The assay shown was conducted in the presence of 10 μ M thymidine to avoid indirect host cell toxicity³⁰ (experiments without thymidine produced indistinguishable results). Experiments were repeated three times and representative data are shown.

unique among apicomplexans in that it acquired a thymidine kinase (TK) by horizontal gene transfer from bacteria²⁵. We hypothesized that TK may also contribute to *Cryptosporidium* antifolate resistance by providing an alternative route to thymidine monophosphate (dTMP; Fig. 4a). For this reason, the TK locus was targeted for insertion, allowing us to test this hypothesis by gene disruption. We mapped the locus in stable transgenic parasites by PCR using primers that link the marker genes with genomic sequences beyond the flanking regions on the targeting construct. This mapping is consistent with insertion by homologous double crossover (Fig. 4b, c). Furthermore, the TK coding sequence is no longer detectable, indicating uniform loss of the gene in the selected population. We tested for DNA incorporation of the thymidine analogue 5-ethynyl-2'-deoxyuridine (EdU) using click chemistry and fluorescence microscopy²⁶. Wild-type parasites grown in the presence of EdU show fluorescent nuclei. This labelling is lost in the transgenic parasites (Fig. 4d, e), confirming loss of TK at the biochemical level. We next treated parasite infected cultures with the antifolate trimethoprim. We confirmed the previously observed resistance in wild-type parasites, but noted enhanced susceptibility in the mutants (Fig. 4f). We conclude that the *C. parvum* TK is a non-essential enzyme required for the activation of thymidine, and that its presence limits the efficacy of antifolate therapy in *Cryptosporidium*.

We show that major hurdles towards genetic analysis and manipulation for cryptosporidiosis can be overcome by maximizing the efficiency of each step of the process and by focusing on *in vivo* propagation and selection. There is an urgent need for new anti-parasitic drugs³. *Cryptosporidium* is not susceptible to drugs widely used against related pathogens, which reflects substantial differences in its metabolism and metabolite uptake²⁷. Luciferase reporter parasites enable phenotypic screening in culture and animals with sufficient sensitivity and specificity to warrant a comprehensive effort to discover novel compounds. Gene deletion now permits biological target validation. Genetic modification may also allow the construction of attenuated parasites as a potential oral vaccine. While infants and toddlers are highly susceptible to the disease, infection is rarely detected in older children^{1,3}. This is consistent with infection studies in people and animals suggesting the development of anti-parasitic and anti-disease immunity^{3,28,29}. A better understanding of the mechanisms underlying disease and protection will be required to design and produce such a vaccine.

Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.

Received 18 May; accepted 12 June 2015.

Published online 15 July 2015.

- Kotloff, K. L. *et al.* Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. *Lancet* **382**, 209–222 (2013).
- Mondal, D. *et al.* Contribution of enteric infection, altered intestinal barrier function, and maternal malnutrition to infant malnutrition in Bangladesh. *Clin. Infect. Dis.* **54**, 185–192 (2012).
- Checkley, W. *et al.* A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. *Lancet Infect. Dis.* **15**, 85–94 (2015).
- Liu, L. *et al.* Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. *Lancet* **379**, 2151–2161 (2012).
- Raja, K. *et al.* Prevalence of cryptosporidiosis in renal transplant recipients presenting with acute diarrhea at a single center in Pakistan. *J. Nephrol.* **3**, 127–131 (2014).
- Hunter, P. R. & Nichols, G. Epidemiology and clinical features of *Cryptosporidium* infection in immunocompromised patients. *Clin. Microbiol. Rev.* **15**, 145–154 (2002).
- Amadi, B. *et al.* Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. *Lancet* **360**, 1375–1380 (2002).
- Amadi, B. *et al.* High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial. *BMC Infect. Dis.* **9**, 195 (2009).

- Striemen, B. Parasitic infections: time to tackle cryptosporidiosis. *Nature* **503**, 189–191 (2013).
- Upton, S. J., Tilley, M. & Brillhart, D. B. Comparative development of *Cryptosporidium parvum* (Apicomplexa) in 11 continuous host cell lines. *FEMS Microbiol. Lett.* **118**, 233–236 (1994).
- Gut, J. & Nelson, R. G. *Cryptosporidium parvum*: synchronized excystation *in vitro* and evaluation of sporozoite infectivity with a new lectin-based assay. *J. Eukaryot. Microbiol.* **46**, 56S–57S (1999).
- Hall, M. P. *et al.* Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate. *ACS Chem. Biol.* **7**, 1848–1857 (2012).
- Abrahamsen, M. S. *et al.* Complete genome sequence of the apicomplexan, *Cryptosporidium parvum*. *Science* **304**, 441–445 (2004).
- Theodos, C. M., Griffiths, J. K., D'Onfro, J., Fairfield, A. & Tzipori, S. Efficacy of nitazoxanide against *Cryptosporidium parvum* in cell culture and in animal models. *Antimicrob. Agents Chemother.* **42**, 1959–1965 (1998).
- Mochizuki, K. High efficiency transformation of *Tetrahymena* using a codon-optimized neomycin resistance gene. *Gene* **425**, 79–83 (2008).
- Gueiros-Filho, F. J. & Beverley, S. M. On the introduction of genetically-modified *Leishmania* outside the laboratory. *Exp. Parasitol.* **78**, 425–428 (1994).
- Fox, B. A., Ristuccia, J. G., Giegley, J. P. & Bzik, D. J. Efficient gene replacements in *Toxoplasma gondii* strains deficient for nonhomologous end-joining. *Eukaryot. Cell* **8**, 520–529 (2009).
- Lee, A. H., Symington, L. S. & Fidock, D. A. DNA repair mechanisms and their biological roles in the malaria parasite *Plasmodium falciparum*. *Microbiol. Mol. Biol. Rev.* **78**, 469–486 (2014).
- Brooks, C. F. *et al.* The *Toxoplasma* apicoplast phosphate translocator links cytosolic and apicoplast metabolism and is essential for parasite survival. *Cell Host Microbe* **7**, 62–73 (2010).
- Jinek, M. *et al.* A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science* **337**, 816–821 (2012).
- Sidik, S. M., Hackett, C. G., Tran, F., Westwood, N. J. & Lourido, S. Efficient genome engineering of *Toxoplasma gondii* using CRISPR/Cas9. *PLoS ONE* **9**, e100450 (2014).
- Griffiths, J. K., Theodos, C., Paris, M. & Tzipori, S. The gamma interferon gene knockout mouse: a highly sensitive model for evaluation of therapeutic agents against *Cryptosporidium parvum*. *J. Clin. Microbiol.* **36**, 2503–2508 (1998).
- Fayer, R., Nerad, T., Rall, W., Lindsay, D. S. & Blagburn, B. L. Studies on cryopreservation of *Cryptosporidium parvum*. *J. Parasitol.* **77**, 357–361 (1991).
- Liu, J., Bolstad, D. B., Bolstad, E. S. D., Wright, D. L. & Anderson, A. C. Towards new antifolates targeting eukaryotic opportunistic infections. *Eukaryot. Cell* **8**, 483–486 (2009).
- Striemen, B. *et al.* Gene transfer in the evolution of parasite nucleotide biosynthesis. *Proc. Natl Acad. Sci. USA* **101**, 3154–3159 (2004).
- Salic, A. & Mitchison, T. J. A chemical method for fast and sensitive detection of DNA synthesis *in vivo*. *Proc. Natl Acad. Sci. USA* **105**, 2415–2420 (2008).
- Striemen, B. in *Antimicrobial Drug Resistance* Vol. 1 (eds Mayers, D. L., Lerner, S. A., Quellet, M. & Sobel, J. D.) 605–621 (Springer, 2009).
- Sheoran, A., Wiffin, A., Widmer, G., Singh, P. & Tzipori, S. Infection with *Cryptosporidium hominis* provides incomplete protection of the host against *Cryptosporidium parvum*. *J. Infect. Dis.* **205**, 1019–1023 (2012).
- McDonald, V., Deer, R., Uni, S., Iseki, M. & Bancroft, G. J. Immune responses to *Cryptosporidium muris* and *Cryptosporidium parvum* in adult immunocompetent or immunocompromised (nude and SCID) mice. *Infect. Immun.* **60**, 3325–3331 (1992).
- Jiang, L., Lee, P. C., White, J. & Rathod, P. K. Potent and selective activity of a combination of thymidine and 1843U89, a folate-based thymidylate synthase inhibitor, against *Plasmodium falciparum*. *Antimicrob. Agents Chemother.* **44**, 1047–1050 (2000).

Supplementary Information is available in the online version of the paper.

Acknowledgements We thank L. Sharling for initial contributions and L. Hedstrom, J. Mead, S. Vaishnav, L. Xiao and Y. Belkaid for discussion. This work was funded in part by the National Institutes of Health (NIH; R01AI112427) to B.S. and by a pilot grant from the Centers for Disease Control and the University of Georgia Research Foundation to B.S. and L. Xiao. M.J.C. was supported by training grant NIH T32AI060546 and B.S. is a Georgia Research Alliance Distinguished Investigator.

Author Contributions S.V. developed the transfection and luciferase assay; M.C.P. optimized transfection and developed the Cas9 system; S.V., M.C.P., A.S. and C.F.B. developed the mouse infection protocol and A.S. developed selection assays; C.F.B. developed surgery; C.J.S. and Y.B.-P. constructed some of the plasmids; and M.J.C. provided bioinformatics support. S.V., M.C.P., A.S. and C.F.B. conducted animal experiments and genotypic and phenotypic characterization. S.V., M.C.P., A.S., C.F.B. and B.S. conceived the study and B.S. wrote the manuscript with contributions from S.V., M.C.P. and A.S.

Author Information Reprints and permissions information is available at www.nature.com/reprints. The authors declare competing financial interests: details are available in the online version of the paper. Readers are welcome to comment on the online version of the paper. Correspondence and requests for materials should be addressed to B.S. (striemen@uga.edu).

METHODS

***C. parvum* reporter and drug resistance vectors.** *C. parvum* transfection vectors were derived from plasmid pH₃BG¹⁹ and modified to contain *C. parvum* promoter and 5' and 3' untranslated messenger RNA regions. We mined the genome and a variety of expression data sets collectively available through Crypto DB (<http://www.cryptodb.org>)³¹ to identify genes that are highly expressed across the life-cycle. Promoters and 5' UTRs of the enolase (cgd5_1960), α -tubulin (cgd4_2860), and aldolase (cgd1_3020) genes and 3' UTRs of enolase (51 bp), α -tubulin (97 bp) or ribosomal protein L13A (cgd5_970, UTR 211 bp) were amplified from genomic DNA by PCR (see Supplementary Table 1 for a list of primer sequences and restriction sites used). Nluc was amplified from pNL1.1 (Promega Corporation), firefly luciferase and different fluorescent protein genes were amplified from vectors used for *T. gondii*^{32–34}. The neomycin resistance gene was amplified from plasmid pNeo4 (ref. 15) (a gift from J. Gaertig, University of Georgia) and introduced 5' or 3' of Nluc in a plasmid with enolase regulatory sequences. To target the *TK* gene, regions flanking the gene were amplified and introduced into the Nluc–Neo vector (the promoter but not the 3' UTR was retained).

***C. parvum* CRISPR/Cas9 genome editing.** Human codon-optimized *Streptococcus pyogenes* Cas9 (hSpCas9) carrying a Flag tag and N- and C-terminal nuclear localization signals was amplified from pX330 (ref. 35) and introduced into the Aldolase–Nluc–ribo vector replacing the Nluc. A guide RNA cassette was synthesized containing the *C. parvum* U6 promoter identified by genome searches using known structural RNA sequences from *Plasmodium falciparum*³⁶, two inverted BbsI restriction sites to facilitate guide cloning, a *trans*-activating CRISPR RNA (tracrRNA) consensus sequence and a terminator (poly T) sequence, and was introduced into the Cas9 plasmid.

To test for CRISPR/Cas9-mediated repair *in vitro*, we modified the codon-optimized Nluc vector by introducing a premature stop codon (Y18Stop) adjacent to a guide target sequence at the beginning of the gene by site-directed mutagenesis (QuikChange II, Agilent Technologies). A 125 bp double-stranded (ds)DNA oligonucleotide was synthesized that restored Y18 and disrupted the PAM motif (G17A) of the guide RNA target, thus rendering it resistant to further Cas9 cuts.

Parasite excystation and transfection. Oocyst excystation was carried out as described¹¹ with some modification. Up to 10⁸ *C. parvum* Iowa strain oocysts (Sterling Parasitology Laboratory or Bunch Grass Farm) were suspended in 100 μ l of 1:4 aqueous dilution of 5.25% sodium hypochlorite and incubated on ice for 5 min. Oocysts were then washed three times with ice-cold PBS, suspended at 3.9 $\times$ 10⁵ oocysts per ml of 0.2 mM sodium taurocholate (prepared in PBS) and incubated at 15 °C (10 min) and then at 37 °C (60–90 min). Emergence of sporozoites was monitored microscopically (typical efficiency 70–90%). Sporozoites were filtered through a 3 μ m polycarbonate filter to remove unexcysted oocysts, washed with ice-cold PBS, and counted.

Initially we used a BTX ECM 630 device for electroporation (Harvard Apparatus). Excysted sporozoites (10⁷) were suspended in complete cytomix buffer (120 mM KCl, 0.15 mM CaCl₂, 10 mM K₂HPO₄/KH₂PO₄, pH 7.6, 25 mM HEPES, pH 7.6, 2 mM EGTA, 5 mM MgCl₂, pH 7.6, supplemented with 2 mM ATP and 5 mM glutathione), mixed with plasmid DNA, and electroporated with a single 1,500 V pulse, resistance of 25 Ω , and a capacitance of 25 μ F. To enhance transfection efficiency, we switched to using the AMAXA Nucleofactor 4D device (Lonza Cologne GmbH). After excystation, 10⁷ sporozoites were suspended in 15 μ l Lonza SF Buffer and combined with 10–50 μ g DNA (prepared in Tris–EDTA, pH 8.0) at a final volume of 20 μ l. The parasite–DNA mix was added to small, strip cuvettes and electroporated using program EH100. Additional electroporation conditions were explored to arrive at this protocol and those are listed in Extended Data Fig. 1.

For *in vitro* transfection assays, human ileocaecal adenocarcinoma (HCT-8) cells (ATCC) were grown in RPMI-1640 with glutamine supplemented with 10% FBS, 1 mM sodium pyruvate, 50 U ml^{−1} penicillin, 50 μ g ml^{−1} streptomycin and amphotericin B in 24-, 48- or 96-well plates to 70% confluency. No effort was made to authenticate this cell line or test for mycoplasma. Prior to infection, media was replaced with DMEM with 2% FBS, 50 U ml^{−1} penicillin, 50 μ g ml^{−1} streptomycin and amphotericin B, and 0.2 mM L-glutamine. For *in vivo* experiments electroporated sporozoites were suspended in PBS and kept on ice until administered to the mice.

The *T. gondii* Nluc plasmid was constructed by inserting the Nluc sequence into vector pCTH₃ (ref. 32) and parasites were electroporated and used to infect human foreskin fibroblasts as described³⁷. HCT-8 cells were cultured in 24-well plates until confluent, transfected with 500 ng of DNA using Lipofectamine 2000 as described by the manufacturer (Life Technologies), and assayed for Nluc activity after 48 h.

Animal ethics statement. Animal experiments were approved by the Institutional Animal Care and Use Committee of the University of Georgia (animal use protocol no. A2012 03-028-Y3-A12).

Surgical delivery of transfected sporozoites into IFN- γ -deficient mice. In preliminary experiments we noted that antibiotic removal of bacterial flora enhances susceptibility of mice. Prior to infection mice were orally treated by gavage daily for a week before infection with an antibiotic cocktail (3 mg ampicillin, 3 mg streptomycin, 0.95 mg metronidazole, 3 mg neomycin and 1.5 mg vancomycin in distilled H₂O, per mouse/per day; all antibiotics purchased from Sigma). To deliver sporozoites directly to the small intestine, we developed a mouse survival surgery protocol for female C57BL/6 IFN- γ -deficient mice (B6.129S7-Ifng^{tm1Ts}/J, Jackson Laboratories) aged 6–8 weeks. The abdominal area of mice was shaved with clippers. Animals were placed in an isoflurane (3–5%) anaesthesia induction chamber and then moved to a nosecone (1–3% isoflurane as needed) on a sterile surgical field. A sterile drape was applied over a warming pad after sterilization of the area with 70% ethanol. Respiration and response to stimulation (toe pinch) were monitored during the procedure and the vaporizer adjusted as needed. Mucous membranes and footpads were monitored for colour to confirm adequate perfusion. Three betadine (Povidone-iodine) scrubs followed by a 70% ethanol wipe were applied to shaved skin before surgery. Ophthalmic ointment (Puralube, Dechra Veterinary Products) was applied to prevent drying of eyes. Skin was vertically incised midline of the abdominal region below the sternum with microsurgical scissors for approximately 1.5 cm followed by vertical incision of the peritoneum. Exposed jejunum/ileum was injected with 10⁷ transfected sporozoites suspended in 200 μ l PBS containing sterile food colouring dye as tracer. After injection, suturing was performed to close the peritoneum. Mice were administered 0.01–0.02 ml per gram body weight of warm lactated Ringer's solution subcutaneously after surgery. Meloxicam analgesic was also administered to the mice after surgery. At completion of the procedure, the eye ointment was wiped off and the vaporizer was turned off and the mice were allowed to breathe the oxygen supply gas until they began to wake. Mice were placed in a recovery area until ambulatory and exhibiting normal respiration and were watched for 2 h after surgery. Incision sites were monitored daily until fully healed (10–14 days). Twenty-four hours after surgical infection, water in mouse cages was replaced with distilled H₂O containing 16 mg ml^{−1} paromomycin, a concentration we determined to deliver a daily dose of 40 mg kg^{−1} paromomycin to each mouse (Extended Data Fig. 3). Mice were randomly assigned to groups before surgery. A sample size of four animals per treatment group was judged to be sufficiently large enough to draw appropriate conclusions. All mice survived surgery and were included in the results reported here. Investigators were not blinded to group allocation during the experiments.

Mouse faeces collection and storage. Faecal samples were collected from mice (typically four mice per cage) starting 3 days after infection every third day for up to a month. Mice were transferred to a fresh, sterile cage for 2–3 h, and faeces from the cage were collected, pooled, and stored at 4 °C.

Luciferase assay. For transient transfection experiments, electroporated sporozoites were added to 70% confluent HCT-8 culture and infection was allowed to proceed at 37 °C for 48 h. Media was removed from wells and 200 μ l of NanoGlo lysis buffer supplemented with NanoGlo substrate (1:50, Promega Corporation) was added to each well. Cells were scraped and the lysate was transferred to white 96-well plates and luminescence was measured using a Synergy H4 Hybrid Microplate Reader (BioTek Instruments). For drug assays with purified stable transgenic oocysts, the culture supernatant was collected after 48 h from 96-well plates. An equal amount of supernatant and NanoGlo lysis buffer with substrate was combined and luminescence was measured.

For luciferase measurement from mouse faecal samples, 20 mg of faeces was weighed into a 1.5-ml microcentrifuge tube and homogenized in 1 ml of lysis buffer (50 mM Tris–HCl, 10% glycerol, 1% Triton-X, 2 mM dithiothreitol (DTT), 2 mM EDTA) using 10–15 glass beads (3 mm) and a vortex mixer for 1 min, followed by clarification of lysate by brief centrifugation. One-hundred microlitres of lysate was mixed with an equal volume of NanoGlo Luciferase Buffer (prepared with 1:50 dilution of substrate) and luminescence was measured as described.

High-throughput imaging assay for parasite growth. For drug assays we used either luciferase activity or a 96-well infection and imaging protocol³⁸ using a BD Pathway instrument. Parasites and host cells were quantified using an ImageJ macro adapted from ref. 39. The ratio of parasites to host nuclei was determined for each sample image and normalized to untreated controls.

For oocyst quantification by high-throughput microscopy, we weighed collected mouse faeces and diluted in PBS (5 μ l mg^{−1}). Samples were incubated at 95 °C for 10 min, vortexing every 2 min at high speed. Large debris was allowed to settle for 10 min, then 10 μ l of the suspension were mixed with 990 μ l PBS and 1 μ l of fluorescein isothiocyanate (FITC)-conjugated goat polyclonal anti-*Cryptosporidium* antibody (GeneTex). After 1 h at room temperature, the sample was centrifuged at 2,000g for 15 min. The pellet was suspended in 200 μ l PBS and transferred to a 96-well plate for microscopy. Plates were imaged using BD Pathway and oocysts were counted

using an ImageJ macro. Using a standard curve (uninfected mouse faeces spiked with known amounts of oocysts), oocyst counts were converted to oocysts per grams faeces.

Quantification of oocyst shedding using qRT-PCR. DNA was extracted from 100 mg faeces using ZR Faecal DNA MiniPrep Kit (Zymo Research Corporation) following the manufacturer's protocol with slight modification. While in lysis buffer, the sample was freeze-thawed in liquid nitrogen five times before the first centrifugation step. Each sample was eluted in 50 µl water, 1 µl of eluate was used for qRT-PCR along with 10 µM primers targeting *Cryptosporidium* 18S rRNA⁴⁰ and SYBR Master Mix (Life Technologies) for detection. Each qRT-PCR reaction was normalized using an eight-point standard curve (faecal DNA purified from uninfected mouse faeces spiked with known amounts of oocysts) for each set of samples.

Oocyst purification from mouse faeces. Oocysts were purified from faeces using sucrose suspension followed by a caesium chloride centrifugation⁴¹. Mouse faeces were suspended in tap water, passed through a 850-µm mesh filter, followed by 250-µm mesh. This filtered suspension was mixed 1:1 with aqueous sucrose solution (specific gravity 1.33), and centrifuged at 1,000g for 5 min. Oocysts were collected from the supernatant and suspended in 0.85% saline solution. 0.5 ml of this preparation was overlaid onto 0.8 ml of 1.15 specific gravity CsCl, and centrifuged for 3 min at 16,000g. Oocysts were collected from the top ml of the sample, washed in 0.85% saline, counted with disposable counting chamber (Kova International) and suspended in 2.5% potassium dichromate for storage at 4 °C.

Western blotting. For western blot analysis, oocysts from wild-type and transgenic Nluc-Neo parasites were excysted as described earlier and sporozoites were lysed in SDS sample buffer. Protein extract from 10⁷ sporozoites was loaded per lane and subjected to electrophoresis on a precast Any kD Mini-PROTEAN TGX gel (Bio-Rad) followed by transfer to 0.2-µm nitrocellulose membrane (Bio-Rad). Blots were blocked and probed with an anti-neomycin phosphotransferase II antibody (EMD Millipore) at 1:1,000 dilution and goat anti-rabbit IgG (H + L)-HRP conjugate (Bio-Rad) at 1:20,000 dilution followed by detection with ECL Western Blotting Substrate (Thermo Pierce) and exposure to film. Equal loading of blots was controlled by stripping and reprobing with an antibody to α -tubulin.

EdU labelling and immunofluorescence microscopy. EdU labelling was performed using the Click-iT EdU Alexa Fluor 594 Imaging Kit following the manufacturer's instructions (Life Technologies). Purified stable transgenic oocysts expressing the luciferase or wild-type oocysts were inoculated into 24-well plates containing coverslips confluent with HCT-8 cells. After 24 h, EdU was added to the media at 10 µM and left for 18 h before fixation. For immunofluorescence, primary antibodies used were mouse monoclonal anti-human neomycin phosphotransferase II (NPII) (Alpha Diagnostic International), rabbit polyclonal

anti-Nluc antibody (Promega Corporation), and polyclonal rabbit anti-*C. parvum* tryptophan synthase B (TrpB; B.S., unpublished observations) at 1:1,000, secondary antibodies were anti-mouse or anti-rabbit conjugated to Alexa488 or Alexa546 (Molecular Probes, Life Technologies) at a dilution of 1:1,000. DNA was visualized with DAPI (2 mg ml⁻¹). Images were collected on an Applied Precision Delta Vision inverted epifluorescence microscope at the UGA Biomedical Microscopy Core, deconvolved and adjusted for contrast using SoftWoRx software.

Statistical methods. All bar graphs depict the mean with standard deviations shown as error bars. Unless indicated otherwise, graphed data represent three technical replicates; each experiment was repeated at least twice and representative data are shown. No statistical tests were used to predetermine sample size. Unpaired *t*-tests were used appropriately to determine statistical significance and a *P* value <0.05 was considered significant. Assumptions for statistical tests were confirmed or corrected as described. No animals were excluded from experimental measurements.

31. Harb, O. S. & Roos, D. S. The Eukaryotic Pathogen Databases: a functional genomic resource integrating data from human and veterinary parasites. *Methods Mol. Biol.* **1201**, 1–18 (2015).
32. van Dooren, G. G., Tomova, C., Agrawal, S., Humbel, B. M. & Striepen, B. *Toxoplasma gondii* Tic20 is essential for apicoplast protein import. *Proc. Natl Acad. Sci. USA* **105**, 13574–13579 (2008).
33. Gubbels, M. J., Li, C. & Striepen, B. High-throughput growth assay for *Toxoplasma gondii* using yellow fluorescent protein. *Antimicrob. Agents Chemother.* **47**, 309–316 (2003).
34. Saeij, J. P., Boyle, J. P., Grigg, M. E., Arrizabalaga, G. & Boothroyd, J. C. Bioluminescence imaging of *Toxoplasma gondii* infection in living mice reveals dramatic differences between strains. *Infect. Immun.* **73**, 695–702 (2005).
35. Cong, L. *et al.* Multiplex genome engineering using CRISPR/Cas systems. *Science* **339**, 819–823 (2013).
36. Chakrabarti, K. *et al.* Structural RNAs of known and unknown function identified in malaria parasites by comparative genomics and RNA analysis. *RNA* **13**, 1923–1939 (2007).
37. Striepen, B. & Soldati, D. in *Toxoplasma gondii: The Model Apicomplexan — Perspective and Methods* (eds Weiss, L. M. & Kim, K.) 391–415 (Elsevier, 2007).
38. Sharling, L. *et al.* A screening pipeline for antiparasitic agents targeting cryptosporidium inosine monophosphate dehydrogenase. *PLoS Negl. Trop. Dis.* **4**, e794 (2010).
39. Bessoff, K., Sateriale, A., Lee, K. K. & Huston, C. D. Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block *Cryptosporidium parvum* growth. *Antimicrob. Agents Chemother.* **57**, 1804–1814 (2013).
40. Mary, C. *et al.* Multicentric evaluation of a new real-time PCR assay for quantification of *Cryptosporidium* spp. and identification of *Cryptosporidium parvum* and *Cryptosporidium hominis*. *J. Clin. Microbiol.* **51**, 2556–2563 (2013).
41. Upton, S. J. in *Cryptosporidium and Cryptosporidiosis* (ed. Fayer, R.) 181–207 (CRC, 1997).

Extended Data Figure 1 | Optimization of sporozoite transfection. a, Ten-million sporozoites prepared in either cytomix (BTX) or Lonza Buffers SE, SF or SG (4D Nucleofection) were combined with 10 μ g DNA (Eno_Nluc-GS-Nluc_Eno). Samples were electroporated using previously determined settings for BTX (1,500 V, 25 Ω , 25 μ F) or various program settings for 4D Nucleofection as indicated. Parasites were added to cultures of HCT-8 cells and luciferase activity was read after 48 h. Bars represent average of two technical replicates. **b,** Transfection was further optimized by comparing the best preliminary settings (buffers SF and SG; programs EH 100 and EO 100) with additional pulse programs as indicated. Transfection was carried out as in

a. Bars represent average of two technical replicates. **c,** Electroporation systems (BTX and 4D Nucleofection) were compared using the same number of *C. parvum* sporozoites and quantities of DNA using buffers and conditions optimized in **a** and **b**. Bars represent average of three technical replicates. Note about tenfold enhancement of transient transfection using 4D Nucleofection. The impact of electroporation on stable transformation cannot be assessed in this setup and may be higher. Experiments in **a** and **b** were done once for the purpose of optimization, while **c** was repeated three times; a single representative experiment is shown.

Extended Data Figure 2 | Direct surgical injection of transfecting *C. parvum* sporozoites into the small intestine. Mice are shaved and anaesthetized with isoflurane (3% initially, then maintained at 1.5% for the surgery). The abdominal skin is disinfected with Betadine and a small incision is made into the peritoneum. Forceps are used to grasp the small intestine and 100 μ l of

PBS containing 10^7 transfecting *C. parvum* sporozoites is injected into the lumen. The peritoneum and the abdominal skin are each sutured with 4-0 polydioxanone and mice are injected with meloxicam (1 mg kg^{-1}) subcutaneously. Each procedure takes around 15 min, and mice recover rapidly.

Extended Data Figure 3 | Optimization of paromomycin treatment of infected mice. **a**, Dosing of mice accounting for drug concentration, animal weight, and measured daily water consumption. At 16 mg ml^{-1} each mouse received 40 mg paromomycin daily (dotted line). **b**, This dose was found to be sufficient to decrease oocyst shedding in treated mice to background. By day 7 mice without paromomycin treatment shed large amounts of oocysts when compared to untreated mice. Treated mice showed no shedding above background. Oocysts were enumerated by high-throughput imaging assay. Five mice were analysed individually with two technical replicates.

Extended Data Figure 4 | Mouse model for selection of stable *C. parvum* transgenics. Repeat of the experiment described in Fig. 3b. **a**, Measurement of *C. parvum* infection using faecal PCR. **b**, Luminescence measurements. Note increasing luminescence from day 6 in parasites that received resistance and Cas9 plasmids. Mice were infected in groups of four per cage and pooled faeces was analysed for each cage (each measurement represents three technical replicates).

Extended Data Figure 5 | *C. parvum* maintains the stable transgene when passed serially in mice without paromomycin treatment. **a**, Mice were infected orally with 100,000 transgenic oocysts. **b**, **c**, Infected mice were then treated with paromomycin (**b**) or left untreated (**c**). Oocysts were purified from faecal collections by sucrose flotation and CsCl centrifugation, and used to infect a second cohort of mice. Again, each mouse received 100,000 transgenic oocysts and mice were treated or not. Faeces were tested for luminescence every 3 days. Each reading represents the pooled faecal sample from five mice with three technical replicates.